文献速递神经肿瘤

成人IDH野生型低级别胶质瘤应进一步分层

Adult IDH wild-type lower-grade gliomas should be further stratified.
PubMed 文献 · Neuro Oncol · 2017-01-01

研究对718例成人WHO II和III级胶质瘤患者进行IDH1/2突变检测,识别出166例IDH野生型病例并检测EGFR、MYB扩增及H3F3A、TERT启动子、BRAF突变。结果显示IDH野生型低级别胶质瘤预后异质,并非均差,可根据分子标记进一步分层。

要点

  • IDH野生型低级别胶质瘤中EGFR扩增、BRAF突变、H3F3A突变分别见于13.8%、6.9%、9.5%,呈互斥模式。
  • TERTp突变见于26.8%的IDH野生型低级别胶质瘤病例。
  • 分子高危组(携带EGFR、H3F3A或TERTp)中位总生存1.23年,分子低危组(三者均无)中位总生存7.63年。

核心结论

  • 成人IDH野生型低级别胶质瘤预后异质,并非均差;应检测MYB、EGFR、TERTp和H3F3A等标记以区分预后良好与不良组。

研究设计与样本

  • 研究对本院718例成人WHO II和III级胶质瘤患者进行重新审阅和IDH1/2突变检测,识别出166例IDH野生型病例进一步检测EGFR和MYB扩增、H3F3A、TERT启动子及BRAF突变。

主要发现

  • IDH野生型低级别胶质瘤中EGFR扩增、BRAF突变、H3F3A突变分别见于13.8%、6.9%、9.5%的患者,呈互斥模式。
  • TERTp突变在26.8%的病例中检出。
  • 年轻年龄、少突胶质细胞表型和II级组织学患者预后较好。
  • 多因素分析证实高龄、非全切除、III级组织学、EGFR扩增和H3F3A突变为独立不良预后因素。
  • 肿瘤进一步分为分子高危组(携带EGFR、H3F3A或TERTp,中位总生存1.23年)和分子低危组(三者均无,中位总生存7.63年),具有独立预后相关性;分子低危组中伴MYB扩增者生存最佳。

临床怎么用

  • 作者认为应检测临床信息和MYB、EGFR、TERTp、H3F3A等额外标记,以界定预后良好与不良的离散组。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Astrocytoma of the isocitrate dehydrogenase (IDH) wild-type gene is described as a provisional entity within the new World Health Organization (WHO) classification. Some groups believe that IDH wild-type lower-grade gliomas, when interrogated for other biomarkers, will mostly turn out to be glioblastoma. We hypothesize that not all IDH wild-type lower-grade gliomas have very poor outcomes and the group could be substratified prognostically. METHODS: Seven hundred and eighteen adult WHO grades II and III patients with gliomas from our hospitals were re-reviewed and tested for IDH1/2 mutations. One hundred and sixty-six patients with IDH wild-type cases were identified for further studies, and EGFR and MYB amplifications, mutations of histone H3F3A, TERT promoter (TERTp), and BRAF were examined. RESULTS: EGFR amplification, BRAF, and H3F3A mutations were observed in 13.8%, 6.9%, and 9.5% of patients, respectively, in a mutually exclusive pattern in IDH wild-type lower-grade gliomas. TERTp mutations were detected in 26.8% of cases. Favorable outcome was observed in patients with young age, oligodendroglial phenotype, and grade II histology. Independent adverse prognostic values of older age, nontotal resection, grade III histology, EGFR amplification, and H3F3A mutation were confirmed by multivariable analysis. Tumors were further classified into "molecularly" high grade (harboring EGFR, H3F3A, or TERTp) (median overall survival = 1.23 y) and lower grade (lacking all of the 3) (median overall survival = 7.63 y) with independent prognostic relevance. The most favorable survival was noted in molecularly lower-grade gliomas with MYB amplification. CONCLUSION: Adult IDH wild-type lower-grade gliomas are prognostically heterogeneous and do not have uniformly poor prognosis. Clinical information and additional markers, including MYB, EGFR, TERTp, and H3F3A, should be examined to delineate discrete favorable and unfavorable prognostic groups.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Aibaidula A, Chan AK, Shi Z, et al. Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol. 2017. PMID: 28575485. doi:10.1093/neuonc/nox078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。